Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B

Biochimica et Biophysica Acta - General Subjects

Volumn 1673, Issue 3, 2004, Pages 186-193

  Guo, Xiao Ning ^a   Zhong, Li ^a   Zhang, Xiu Hua ^a   Zhao, Wei Min ^a   Zhang, Xiong Wen ^a   Lin, Li Ping ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

adenosine triphosphate; Anti cancer drug; ATP; dimethyl sulfoxide; dithiothreitol; DMSO; DTT; EGF; epidermal growth factor; ErbB 2; PBS; phenylmethylsulfonyl fluoride; PMSF; receptor tyrosine kinases; RTKs; SDS; sodium dodecyl sulfate; Tyrosine kinase inhibitor; ZH 4B

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; DIVALENT CATION; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ZH 4B;

ARTICLE; CANCER CELL CULTURE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; CATALYTIC DOMAIN; CATIONS, DIVALENT; CELL LINE, TUMOR; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; HUMANS; PHOSPHORYLATION; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 3242798249     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2004.04.015     Document Type: Article

References (25)

1. Traxler P., Bold G., Buchdunger E., Caravatti G., Furet P., Manley P., O'Reilly T., Wood J., Zimmermann J. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21:2001;499-512
2. Moasser M.M., Basso A., Averbuch S.D., Rosen N. The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexressing Tumor Cells. Cancer Res. 61:2001;7184-7188
3. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 19:2000;6550-6565
4. Guy P.M., Carraway K.L. III, Cerione R.A. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases. J. Biol. Chem. 267:1992;13851-13858
5. Chan P.M., Nestler H.P., Miller W.T. Investigating the substrate specificity of the HER2/Neu tyrosine kinase using peptide libraries. Cancer Lett. 160:2000;159-169
6. Osherov N., Gazit A., Gilon C., Levitzki A. Selective inhibition of the epidermal growth factor and HER2/Neu receptors by tyrphostins. J. Biol. Chem. 268:1993;11134-11142
7. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 267:1995;1782-1788
8. Spencer K.S.R., Graus-Porta D., Leng J., Hynes N.E., Klemke R.L. ErbB2 is necessary for induction of carcinoma cell invasionby ErbB family receptor tyrosine kinases. J. Cell Biol. 148:2000;385-397
9. Favoni R.E., Cupis A.D. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol. Rev. 52:2000;179-206
10. Citri A., Alroy I., Lavi S., Rubin C., Xu W., Grammatikakis N., Patterson C., Neckers L., Fry D.W., Yarden Y. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 21:2002;2407-2417
11. Christensen J.G., Schreck R.E., Chan E., Wang X., Yang C., Liu L., Cui J., Sun L., Wei J., Cherrington J.M., Mendel D.B. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin. Cancer Res. 7:2001;4230-4238
12. Shawver L.K., Slamon D., Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 1:2002;117-123
13. Parast C.V., Mroczkowski B., Pinko C., Misialek S., Khambatta G., Appelt K. Characterization and kinetic mechanism of catalytic domain of human Vascular Endotheial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry. 37:1998;16788-16801
14. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., Stuart J.D., Blackburn K., Moyer M.B., Alligood K.J., Knight W.B., Wood E.R. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. J. Biol. Chem. 277:2002;1576-1585
15. Racker E. Use of synthetic amino acid polymers for assay of protein-tyrosine and protein-serine kinases. Methods Enzymol. 200:1991;107-111
16. Monilola A.O., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:2000;3159-3167
17. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., Lavi S., Seger R., Ratzkin B.J., Sela M., Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15:1996;2452-2467
18. Arteaga C.L., Chinratanalab W., Carter M.B. Inhibitors of HER2/neu (erbB-2) signal transduction. Semin. Oncol. 28:2001;30-35
19. Yang Y., Spitzer E., Meyer D., Sachs M., Niemann C., Hartmann G., Weidner K.M., Birchmeier C., Birchmeier W. Sequential requirement of HGF and neuregulin in the morphogenesis and differentiation of the mammary gland. J. Cell Biol. 131:1995;215-226
20. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Mol. Cell. Biol. 2:2001;127-137
21. Cobb M.H., Sang B.C., Gonzalez R., Goldsmith E., Ellis L. Auto-phosphorylation activates the soluble cytoplasmic domain of the insulin receptor in an intermolecular reaction. J. Biol. Chem. 264:1989;18701-18706
22. Wei L., Hubbard S.R., Hendrickson W.A., Ellis L. Expression, characterization, and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain. J. Biol. Chem. 270:1995;8122-8130
23. Mohammadi M., Schlessinger J., Hubbard S.R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell. 86:1996;577-587
24. Homann S., Schacher B., Zumstein-Mecker S., Fabbro D., Bold G., Ferrari S. Expression and purification of human recombinant GST-FGF receptor-1. J. Biotechnol. 86:2001;51-58
25. Zhuang S.F., Zhou C.H., Qian J., Qian Z., Shibuya M., Ye Q.Z. A new model for random screening inhibitors of vascular endothelial growth factor receptor 1 kinase. Acta Pharmacol. Sin. 23:2002;117-123